Aachen, Germany – September 21, 2026 -- Grünenthal has agreed to acquire Bayer AG's oncology drug Stivarga® (regorafenib) for up to €375 million, adding an oral cancer treatment sold in more than 90 markets to its portfolio.
Grünenthal expects Stivarga to add up to €100 million to EBITDA in 2027
The German pharmaceutical company said the acquisition is immediately accretive to its business, with an estimated positive impact on consolidated EBITDA of approximately €100 million for the year ending December 31, 2027. That projection assumes the deal closes by the end of 2026 or early 2027 and includes a full year of consolidation.
Stivarga treats colorectal, liver and gastrointestinal cancers
Stivarga is an oral multikinase inhibitor approved for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have exhausted other treatment options. The drug has treated more than one million patients across over 90 countries over the past decade.
Deal closing is pending regulatory approval, expected by early 2027
The transaction is subject to customary closing conditions, including sign-off from relevant regulatory authorities. Grünenthal anticipates loss of exclusivity for Stivarga in 2029 in the European Union and 2030 in the United States.
CEO Gabriel Baertschi calls the deal a "strong strategic fit"
"Stivarga has a well-established role in patient care and the transaction is immediately accretive to our business,